Notícias

Eli Lilly stock toppled Monday after a patient taking its new weight-loss pill, Foundayo, experienced liver failure.

I keep buying Eli Lilly (NYSE:LLY), and the latest quarter just made it harder to stop. This is a confession of conviction. I have been adding through every dip in 2026, and the most recent earnings report told me the thesis is accelerating. What pulls me back to the buy button is simple. Lilly sits ... This Pharma Stock Keeps Earning My Money, Here’s Why

Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Over the last 7 days, the United States market has remained flat, although it has experienced a notable 28% increase over the past year and earnings are forecast to grow by 16% annually. In this context of overall growth, identifying stocks that may be trading below their fair value can offer opportunities for investors seeking to capitalize on potential undervaluation in the market.

Lilly's weight loss drugs have been delivering blockbuster revenue.

A new weight loss pill is expanding the pharmaceutical leader's already massive market opportunity.

Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]

Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. Cramer noted that the company is “creating a lot of jobs,” as he said: Okay, then there’s one that’s totally away from manufacturing or industry or tech, and that’s Eli Lilly. It was up 10%. […]

Eli Lilly and Company ( NYSE:LLY ) investors will be delighted, with the company turning in some strong numbers with...

Growth investors picking a large-cap vehicle in 2026 face a real choice: pay nothing for a passive index, or pay a few basis points for an active manager who claims to add value. The Fidelity Enhanced Large Cap Growth ETF (NYSEARCA:FELG) sits squarely in that second camp, charging 0.18% for an actively managed take on ... Why Growth Investors Are Ditching FELG for the NASDAQ-100’s 9.74% Edge

Blockbuster sales of its flagship GLP-1 treatments have propelled Eli Lilly And Co.‘s first-quarter earnings, prompting a prominent Wall Street analyst to defend the stock’s valuation and highlight the disruptive potential of its new oral weight-loss drug. Fueling The ‘Love Affair’ Eli Lilly's revenue skyrocketed 56% year-over-year to $19.8 billion during its first-quarter 2026, driven primarily by the astronomical volume demand for its metabolic and weight-management medications. Following the

Inspire Medical Systems (NYSE:INSP) highlighted revenue growth, product innovation, and a series of governance and compensation-related items that won stockholder approval at its 2026 annual meeting held virtually on April 30, 2026. Management highlights 2025 performance and milestones Timothy P. H

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.3% in the morning session after the stock continued to rally as the company reported strong first-quarter 2026 financial results that surpassed analyst expectations and raised its full-year guidance.

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares on April 17, following encouraging Phase 3 trial outcomes for Foundayo in type 2 diabetes. Eli Lilly & Company (NYSE:LLY) reported the […]

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19.8 billion. The company’s full-year revenue guidance of $83.5 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $8.55 per share was 25.9% above analysts’ consensus estimates.

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners, even as analysts continue to weigh how much growth is already priced into the stock. Bank of America reiterated its Buy rating on Eli Lilly and set a $1,133 ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development.

Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly approved oral obesity therapy, and a slate of pipeline and business development milestones. Founday

The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.

Veeva Systems stock pops following S&P 500 inclusion announcement.

Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid

Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, w

Assessing Eli Lilly after a strong multi year run Eli Lilly (LLY) is back in focus for many investors after a long stretch of strong multi year total returns and significant scale, with a market value around US$761.7b and annual revenue of US$65.2b. See our latest analysis for Eli Lilly. The latest 9.8% 1 day share price return takes Eli Lilly to US$934.60, while the 1 year total shareholder return of 18.56% and 5 year total shareholder return above 4x suggest long term momentum has remained...

Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.

Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali

Qorvo downgraded, Ulta Beauty upgraded: Wall Street's top analyst calls

Among the best stocks in earnings performance, Comfort Systems has a pristine 99 EPS Rating, the highest in IBD's air conditioning and heating products industry group.